Discovering CHD6: A Potential Drug Target and Biomarker (G84181)

Target Name: CHD6

NCBI ID: G84181

CHD6

Discovering CHD6: A Potential Drug Target and Biomarker

CHD6 (Chromosomal Deletion-Induced gene B protein) is a protein that is expressed in various tissues and cells of the human body. It is a key regulator of the cell cycle and has been implicated in the development and progression of many diseases, including cancer. In this article, we will discuss the research on CHD6 as a potential drug target and biomarker.

The CHD6 gene

The CHD6 gene is located on chromosome 16 and encodes a protein that is essential for the regulation of the cell cycle. The protein has a molecular weight of approximately 42 kDa and consists of 152 amino acids. CHD6 is composed of a cytoplasmic domain, a transmembrane domain, and an extracellular domain.

The cytoplasmic domain of CHD6 is responsible for the protein's stability and functions as a scaffold. It is involved in the regulation of the actin-associated protein (AP-1) and the interaction between the protein and microtubules.

The transmembrane domain of CHD6 is responsible for the protein's localization and interactions with other cellular components. It is involved in the regulation of the cell cycle and has been implicated in the development and progression of many diseases.

The extracellular domain of CHD6 is responsible for the protein's interactions with the cell surface and other proteins. It is involved in the regulation of the cell cycle and has been implicated in the development and progression of many diseases.

CHD6 as a drug target

CHD6 has been identified as a potential drug target due to its involvement in the regulation of the cell cycle and its association with the development and progression of many diseases. Several studies have shown that inhibiting the activity of CHD6 can lead to the inhibition of the growth and survival of cancer cells.

One of the main targets of CHD6 is the protein p21, which is a negative regulator of the cell cycle. Inhibition of CHD6 has been shown to lead to the activation of p21 and the inhibition of its degradation, leading to the accumulation of p21 in the cell and the inhibition of its degradation. This has been shown to lead to the inhibition of cell growth and the inhibition of the progression of the cell cycle.

Another target of CHD6 is the protein p53, which is a positive regulator of the cell cycle. Inhibition of CHD6 has been shown to lead to the inhibition of p53 and the accumulation of p53 in the cell, leading to the inhibition of its function. This has been shown to lead to the inhibition of cell growth and the inhibition of the progression of the cell cycle.

CHD6 as a biomarker

CHD6 has also been identified as a potential biomarker for the diagnosis and prognosis of many diseases. Several studies have shown that the expression of CHD6 is significantly associated with the development and progression of many diseases, including cancer.

One of the main biomarkers for cancer is the expression of the protein PD-L1, which is a negative regulator of immune responses. Inhibition of CHD6 has been shown to lead to the activation of PD-L1 and the inhibition of its function, leading to the activation of immune responses and the development of cancer.

Another biomarker for cancer is the expression of the protein G2000, which is a positive regulator of the cell cycle. Inhibition of CHD6 has been shown to lead to the inhibition of G2000 and the accumulation of p53 in the cell, leading to the inhibition of its function. This has been shown to lead to the inhibition of cell growth and the inhibition of the progression of the cell cycle.

Conclusion

In conclusion, CHD6 is a protein that is involved in the regulation of the cell cycle and has been implicated in the development and progression of many diseases. As a potential drug target and biomarker, CHD6 is a promising target for the development of new treatments for cancer and other diseases. Further research is needed to fully understand the role of CHD6 in the development and progression of diseases.

Protein Name: Chromodomain Helicase DNA Binding Protein 6

Functions: DNA-dependent ATPase that plays a role in chromatin remodeling. Regulates transcription by disrupting nucleosomes in a largely non-sliding manner which strongly increases the accessibility of chromatin (PubMed:28533432). Activates transcription of specific genes in response to oxidative stress through interaction with NFE2L2

The "CHD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets